Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
University of Pittsburgh
Bristol-Myers Squibb
Groupe Oncologie Radiotherapie Tete et Cou
National Cancer Institute (NCI)
Bristol-Myers Squibb
National Cancer Institute (NCI)
Karolinska University Hospital
H. Lee Moffitt Cancer Center and Research Institute
Aulos Bioscience, Inc.
M.D. Anderson Cancer Center
Exelixis
Vanderbilt-Ingram Cancer Center
Neonc Technologies, Inc.
Yonsei University
University of Michigan Rogel Cancer Center
ImmunityBio, Inc.
Yale University
University of Pittsburgh
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Pittsburgh
Mayo Clinic
BicycleTx Limited
Medical University of South Carolina
Roswell Park Cancer Institute
University of Pittsburgh
Nanobiotix
Case Comprehensive Cancer Center
Hookipa Biotech GmbH
Incyte Corporation
Emory University
Providence Health & Services
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Iovance Biotherapeutics, Inc.
Dana-Farber Cancer Institute
Thomas Jefferson University
Oslo University Hospital
University of Chicago
Gustave Roussy, Cancer Campus, Grand Paris
Groupe Oncologie Radiotherapie Tete et Cou
University of Chicago
Thomas Jefferson University
Bayer
Bristol-Myers Squibb
University of California, San Diego
Replimune, Inc.
The Clatterbridge Cancer Centre NHS Foundation Trust
ImmunityBio, Inc.
University of Pittsburgh
University of Pittsburgh